

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 22862-0003US1	Application No. 10/598,486
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Yu et al.	
		Filing Date August 31, 2006	Group Art Unit 1644
(37 CFR §1.98(b))			

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	5,844,075	12/01/1998	Kawakami et al.			
	2	6,010,905	01/04/2000	Cohen et al.			
	3	2002/0182194	12/05/2002	Ju et al.			
	4	2003/0064916	04/03/2003	Sherman			
	5	2010/0135975	06/03/2010	Yu et al.			
	6	2010/0310643	12/09/2010	Singh et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	7	WO 2006/034334	03/30/2006	WIPO				
	8	WO 2010/028066	03/11/2010	WIPO				
	9	WO 2010/129895	11/11/2010	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	10	ABDEL-WAHAB et al., "Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity," Cell. Immunol., 186:63-74 (1998)
	11	BODEY et al., "Cyclooxygenase-2 (COX-2) overexpression in childhood brain tumors," In Vivo, 20:519-525 (2006)
	12	CASEY et al., "Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine," Immunology, 110:105-111 (2003)
	13	CHO et al., "Recent advances of dendritic cells (DCs)-based immunotherapy for malignant gliomas," Cell Transplant., 18:977-983 (2009)
	14	CZERNIECKI et al., "Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion," Cancer Res., 67:1842-52 (2007)
	15	DAUER et al., "Chemosensitization of pancreatic carcinoma cells to enhance T cell-mediated cytotoxicity induced by tumor lysate-pulsed dendritic cells," J. Immunother., 28:332-342 (2005)
	16	DENKERT et al., "Prognostic impact of cyclooxygenase-2 in breast cancer," Clin. Breast Cancer, 4:428-433 (2004)
	17	GASPARINI et al., "Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?" Lancet Oncol., 4:605-615 (2003)
	18	IRVIN et al., "T cells enhance stem-like properties and conditional malignancy in gliomas," PLoS One, 5:e10974 (2010)
	19	KUBY et al., Immunology, W. H. Freeman and Co., pp. 523-524 (1992)

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 22862-0003US1	Application No. 10/598,486
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Yu et al.	
		Filing Date August 31, 2006	Group Art Unit 1644
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	20	LEFRANC, "Editorial: On the road to multi-modal and pluri-disciplinary treatment of glioblastomas," Acta Neurochir. (Wien), 151:109-112 (2009)
	21	LIAO et al., "Cyclo-oxygenase-2 and its inhibition in cancer: is there a role?" Drugs, 67:821-845 (2007)
	22	LIU et al., "Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma," Mol. Cancer, 5:67 (2006)
	23	LIU et al., "Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma," Cancer Control, 10:138-147 (2003)
	24	LIU et al., "Chemoresistance of stem-like cells isolated from glioblastoma," Proc. Amer. Assoc. Cancer Res., 47:75, abstract #320 (2006) (cited in 22862-0006EP1)
	25	LIU et al., "AIM-2: a novel tumor antigen is expressed and presented by human glioma cells," J. Immunother., 27:220-226 (2004)
	26	LIU et al., "HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells," Cancer Res., 64:4980-86 (2004)
	27	MELCHER et al., "Dendritic cells for the immunotherapy of cancer," Clin. Oncol., 14:185-192 (2002)
	28	OGINO et al., "Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer," Clin. Cancer Res., 14:8221-27 (2008)
	29	OHNO et al., "Multiple roles of cyclooxygenase-2 in endometrial cancer," Anticancer Res., 25:3679-87 (2005)
	30	PARMIANI et al., "Cancer immunotherapy with peptide-based vaccines: What have we achieved? Where are we going?" J. Natl. Cancer Inst., 94:805-818 (2002)
	31	PARNEY et al., "Glioma immunology and immunotherapy," Neurosurgery, 46:778-791 (2000)
	32	SOLING et al., "Dendritic cell therapy of primary brain tumors," Mol. Med., 7:659-667 (2001)
	33	SOUMAORO et al., "Cyclooxygenase-2 expression: A significant prognostic indicator for patients with colorectal cancer," Clin. Cancer. Res., 10:8465-71 (2004)
	34	TAKAGI et al., "Anti-tumor effects of dendritic and tumor cell fusions are not dependent on expression of MHC class I and II by dendritic cells," Cancer Lett., 213:49-55 (2004)
	35	WESTPHAL et al., "Other experimental therapies for glioma," Recent Results Cancer Res., 171:155-164 (2009)
	36	YANG et al., "Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme," J. Neurosurg., 100:310-319 (2004)
	37	YOUNG et al., "Cyclooxygenase-2 in cervical neoplasia: a review," Gynecol. Oncol., 109:140-145 (2008)
	38	YUAN et al., "Isolation of cancer stem cells from adult glioblastoma multiforme," Oncogene, 58:9392-9400 (2004)
	39	ZAGZAG et al., "Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain," Lab. Invest., 85:328-341 (2005)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	